Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Testing long-acting somatostatin analogues during radioactive peptide therapy for neuroendocrine tumors
Tests whether continued long-acting somatostatin analogues affect tumor dose in adults with neuroendocrine tumors.
Key facts
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 34 people, planned
- Started
- 17 Jun 2024
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 17 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed neuroendocrine tumour who qualify for PRRT (peptide receptor radionuclide therapy). It studies how continuing long-acting somatostatin analogue drugs changes the radiation dose reaching tumour lesions.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Neuroendocrine tumour grade I and II confirmed by tissue examination. At least one soft tissue lesion larger than 2 cm (0.8 in). ECOG performance status 0-2.
- Earlier treatment
- Must be able to stop long-acting somatostatin analogues (LA-SSA) for 4-6 weeks. Must not use short-acting somatostatin analogues.
Main reasons for not taking part
- Cannot stop LA-SSA for 4-6 weeks
- Uses short-acting somatostatin analogues
- Cannot follow the study procedures
- Factors that may change how the drug spreads in the body, for example furosemide right after the infusion, limited fluid intake or renal catheters
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 18 years
- Able to provide spoken and written informed consent for the trial
- Histopathological confirmed neuroendocrine tumor
- Fulfill the clinical criteria for PRRT
- At least one soft tissue lesion > 2 cm
- Aimed administered activity of 7400 MBq
- ECOG score (performance status) 0-2
Who cannot take part
- Not possible to discontinue LA-SSA for 4-6 weeks
- Use of short-acting somatostatin analogues
- Inability to comply to the study procedures
- Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.)
- Pregnancy and lactating female patients
Where in Netherlands
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
About the trial
What the trial wants to find out
The effect of continued LA-SSA use on the absorbed dose in tumor lesions during PRRT.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial
- Plain-language title
- Testing long-acting somatostatin analogues during radioactive peptide therapy for neuroendocrine tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 17 June 2026